HOME >> MEDICINE >> NEWS
Canadian discovery promises treatment for HIV dementia

VANCOUVER, CANADA -- Millions of HIV patients who suffer from dementia now have hope of a treatment, thanks to a breakthrough discovery by Canadian researchers.

Scientists from the University of Calgary in Alberta and the University of British Columbia in Vancouver have found that HIV triggers an enzyme in white blood cells that kills nerve cells in the brain. The enzyme, known as Metalloproteinase-2 or MMP2, changes a molecule required for normal brain growth and function. The altered molecule becomes highly toxic and destroys brain nerve cells, giving rise to symptoms of dementia.

It is the first study to unravel the mechanics of how dementia and memory loss is caused in HIV patients. In addition, the researchers also found they could block the toxic effects of MMP2 by using drugs already in clinical trials for cancer treatment.

"We now understand how this enzyme becomes a killing machine," says Christopher Overall, Canada Research Chair in Metalloproteinase Biology at UBC. "This is exciting news for patients because we think dementia can be slowed or stopped by adding another protease blocker to the drug cocktails now used to treat HIV."

More than 20 per cent of people with AIDS experience dementia during the course of their illness. A rapidly progressive condition, HIV dementia is characterized by impaired concentration and problem solving, forgetfulness, as well as motor abnormalities such as slurred speech and difficulties with movement.

The findings of the two-year study, completed with principal co-investigator Christopher Power of the University of Calgary, were reported recently in Nature Neuroscience. Members of Overall's lab at the UBC Faculty of Dentistry completed biochemical assays and identified the toxic protein that allowed Power, a neurologist who treats people with HIV dementia, to test MMP2 on HIV-infected cells.

"The team and I are revved up about the new avenues of potential treatment for pe
'"/>

Contact: Hilary Thomson
hilary.thomson@ubc.ca
604-822-2644
University of British Columbia
5-Nov-2003


Page: 1 2

Related medicine news :

1. U of T researchers describe Joe Canadian tongue
2. Canadian neurologist wins highest award as American Stroke Association honors five
3. Canadian researchers important discovery in HIV research
4. Impact of 2002 Canadian forest fires felt 700 miles away in Baltimore, Maryland
5. Canadian researchers to develop smart drug to repair psychiatric disorders
6. McMaster named Canadian Research University of the Year
7. Safety of Canadian hospitals
8. Patient safety study provides first national estimate of adverse events in Canadian hospitals
9. Canadian doctors dont know costs of prescribed treatments
10. New Canadian study demonstrates clear survival benefit of treatment in trials and at large centres
11. Most Canadian hospitals below recommended standards

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Canadian discovery promises treatment for HIV dementia

(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... ZIONA, Israel , August 3, ... TASE: BVXV) today announced it received the statistical analysis of ... vaccine (M-001), administered in the BVX-005 phase II trial which ... future strains which did not exist at the time of ... (flu) strain that caused the epidemic in the ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
Cached News: